TNF-alpha antagonist | Drug design | Routes of administration | Usual frequency of maintenance therapy* | Therapeutic differences |
Etanercept and biosimilars to etanercept | Soluble p75 TNF-alpha receptor fusion protein | Subcutaneous | Once weekly |
|
Adalimumab and biosimilars to adalimumab | Fully human anti-TNF-alpha monoclonal antibody | Subcutaneous | Every 2 weeks | |
Infliximab and biosimilars to infliximab | Chimeric (mouse/human) anti-TNF-alpha monoclonal antibody | Subcutaneous (biosimilar) or intravenous | Every 2 weeks (subcutaneous) or Every 4 to 8 weeks (intravenous) | |
Certolizumab pegol | Antigen-binding fragment (Fab') of a humanized monoclonal antibody coupled to polyethylene glycol | Subcutaneous | Every 2 to 4 weeks |
|
Golimumab | Human anti-TNF-alpha monoclonal antibody | Subcutaneous or intravenous | Every 4 weeks (subcutaneous) or Every 8 weeks (intravenous) |
TNF: tumor necrosis factor.
* Frequency may vary by therapeutic indication. Please refer to UpToDate content on specific disease topics.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟